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Abstract
Back pain is the #1 cause of years lived with disability worldwide, yet surprisingly little is
known regarding the biology underlying this symptom. We conducted a genome-wide asso-
ciation study (GWAS) meta-analysis of chronic back pain (CBP). Adults of European ances-
try were included from 15 cohorts in the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium, and from the UK Biobank interim data release. CBP
cases were defined as those reporting back pain present for3–6 months; non-cases
were included as comparisons (“controls”). Each cohort conducted genotyping using com-
mercially available arrays followed by imputation. GWAS used logistic regression models
with additive genetic effects, adjusting for age, sex, study-specific covariates, and population
substructure. The threshold for genome-wide significance in the fixed-effect inverse-vari-
ance weighted meta-analysis was p<5×10−8. Suggestive (p<5×10−7) and genome-wide sig-
nificant (p<5×10−8) variants were carried forward for replication or further investigation in the
remaining UK Biobank participants not included in the discovery sample. The discovery sam-
ple comprised 158,025 individuals, including 29,531 CBP cases. A genome-wide significant
association was found for the intronic variant rs12310519 in SOX5 (OR 1.08, p = 7.2×10−10).
This was subsequently replicated in 283,752 UK Biobank participants not included in the dis-
covery sample, including 50,915 cases (OR 1.06, p = 5.3×10−11), and exceeded genome-
wide significance in joint meta-analysis (OR 1.07, p = 4.5×10−19). We found suggestive asso-
ciations at three other loci in the discovery sample, two of which exceeded genome-wide sig-
nificance in joint meta-analysis: an intergenic variant, rs7833174, located between CCDC26
and GSDMC (OR 1.05, p = 4.4×10−13), and an intronic variant, rs4384683, in DCC (OR 0.97,
p = 2.4×10−10). In this first reported meta-analysis of GWAS for CBP, we identified and repli-
cated a genetic locus associated with CBP (SOX5). We also identified 2 other loci that
reached genome-wide significance in a 2-stage joint meta-analysis (CCDC26/GSDMC and
DCC).
Author summary
Back pain is the #1 cause of years lived with disability worldwide and one of the most com-
mon reasons for health care visits in developed countries, yet surprisingly little is known
regarding the biology underlying this symptom. Chronic back pain is the major driver of
the societal burden of back pain. Identifying biological pathways involved in chronic back
pain through genetic association studies might reveal insights into the underlying mecha-
nisms involved or suggest potential avenues for the development of new treatments. We
conducted the first genome-wide association study meta-analysis to examine genetic vari-
ants associated with chronic back pain. We identified variants associated with chronic
Genome-wide meta-analysis of chronic back pain
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back pain in 158,025 individuals of European ancestry from 16 cohorts in Europe and
North America, and replicated our findings in 283,752 UK Biobank participants of Euro-
pean ancestry not included in the discovery sample. Our study identifies three novel
genome-wide significant associations with chronic back pain, and suggests possible shared
genetic mechanisms with other traits such as cartilage, osteoarthritis, lumbar disc degen-
eration, depression, and height/vertebral development.
Introduction
Back pain causes more years lived with disability than any other health condition worldwide.
[1] Although most adults experience a new (‘acute’) episode of back pain at some point in
their lives, the societal burden of back pain is driven by the minority of individuals who fail to
recover from such episodes and go on to develop persistent (‘chronic’) back pain.[2] Chronic
back pain (CBP) has a number of definitions but is most often considered as back pain of dura-
tion3 months in clinical practice, and a duration of6 months is also commonly used in
research.[3, 4]
Back pain is moderately heritable. Meta-analysis of 11 twin studies of back pain indicates a
heritability of 40%, with a pattern of monozygotic (rMZ = 0.56) and dizygotic (rDZ = 0.28) twin
correlations suggesting an additive genetic model (2rDZ = rMZ).[5, 6] Heritability is greater for
chronic than for acute back pain.[7] Nevertheless, genetic studies attempting to identify spe-
cific genetic markers for CBP have to date been limited to small studies using the candidate
gene approach.[8, 9] Although CBP is often attributed to anatomic changes such as interverte-
bral disc degeneration or disc herniation, such findings have only weak association with CBP,
[10, 11] and explain only a small proportion (7–23%) of the genetic influence on back pain
[12]. The unexplained genetic contribution to CBP may involve not only spine pathology but
also functional predisposition to chronic pain involving higher-order neurologic processes
related to the generation and maintenance of pain.[13–15] Furthermore, psychological factors
such as depression are widely recognized as important risk factors for CBP.[16] Given the
range of processes that might contribute to CBP, the agnostic genome-wide association
approach may identify novel genetic variants associated with CBP and provide insights into
underlying biological mechanisms not previously considered.
This research was an international collaboration between investigators from the Cohorts
for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Musculo-
skeletal Workgroup[17] and the European Union FP7 project Pain-OMICS (‘Multi-dimen-
sional omics approach to stratification of patients with low back pain’). We conducted a meta-
analysis of GWAS of CBP in adults of European ancestry from 16 community- and popula-
tion-based cohorts, including those from the CHARGE and PainOmics consortia, and the
UK Biobank. The aim was to identify novel associations between specific genetic markers and
CBP, and elucidate the biological mechanisms underlying this condition.
Results
Study overview
Genome-wide discovery meta-analysis was comprised of adults of European ancestry from 16
cohorts (n = 158,025 including 29,531 CBP cases; Table 1), including 15 CHARGE cohorts
and participants from the UK Biobank (UKB) interim data release (UKB1). After quality con-
trol, the number of SNPs included in the meta-analysis ranged from 6,205,227 to 9,775,703,
Genome-wide meta-analysis of chronic back pain
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depending on the cohort (S1 and S2 Tables). Linkage disequilibrium (LD) score regression
(LDsr) was used distinguish polygenicity from potential confounding,[18] using LD scores
from European ancestry 1000 Genomes data. The genome-wide significance level was defined
as p<5×10−8, and suggestive significance level was defined as p<5×10−7, after using the LDsr
intercept as a correction factor. For those SNPs of genome-wide suggestive significance in the
discovery phase, replication was conducted in a sample of UKB European ancestry participants
(UKB2) who were not part of the interim data release (n = 283,752 subjects, including 50,915
CBP cases), and a joint (discovery-replication) meta-analysis was performed. We then con-
ducted functional characterization of variants and loci achieving genome-wide significance in
the joint meta-analysis.
Meta-analysis of GWAS of CBP
The characteristics of cohorts included in the discovery meta-analysis are shown in Table 1.
The mean age of participants in each cohort ranged between 53–76 years. Within cohorts,
mean age, BMI, and proportion of females was more often higher among CBP cases than
among those without CBP. A quantile-quantile plot comparing the meta-analysis association
results with those expected by chance is presented in S1 Fig. The LDsr intercept was 1.007
(standard error 0.006), λ was 1.114, and the LDsr ratio was 0.0581 (standard error 0.053), pro-
viding no evidence of inflation of p-values from population stratification. Meta-analysis results
are summarized in the Manhattan plot shown in Fig 1.
A genome-wide significant association (OR 1.08, p = 7.2×10−10) was found for rs12310519
on chromosome 12 in an intronic region of SOX5, with little evidence for heterogeneity
(I2 = 0, p = 0.95) (Table 2, S2 Fig). Several other signals were in high LD (r2>0.8) with the top
signal (S3 Fig), but none were independently associated with CBP in analyses conditional on
rs12310519.
No other variants achieved genome-wide significance, but variants in three other loci
reached suggestive significance (Table 2, S3 Table, S4–S9 Figs): rs1453867 (OR 0.95,
p = 7.7×10−8), located in an intronic region of chromosome 2 within DIS3L2; rs7833174 (OR
1.06, p = 1.0×10−7), located in an intergenic region on chromosome 8 between CCDC26 (a
long non-coding RNA) and GSDMC; and rs4384683 (OR 0.95, p = 3.2×10−7), located in an
intronic region of chromosome 18 within DCC. In each of these 3 regions, there was no other
variant reaching the suggestive significance level in analyses conditional on the lead SNP in the
region. Post hoc secondary analyses of the discovery sample showed effects of similar magni-
tude and direction between the CHARGE cohorts and the UKB interim data release for associ-
ations between the lead variants in the top 4 loci and CBP (S4 Table).
We examined these 4 top variants in 283,752 UKB individuals not included in the discovery
sample (UKB2), including 50,915 cases (Table 2). For all 4 variants, the direction of association
was the same in discovery and replication. The association for rs12310519 in SOX5 replicated
in UKB2 (OR 1.06, p = 5.3×10−11), and exceeded genome-wide significance in the joint analy-
sis (OR = 1.07, p = 4.5×10−19). Of the 3 suggestive-significance variants from the discovery
stage, rs7833174 at CCDC26/GSDMC (OR 1.05, p = 4.4×10−13) and rs4384683 in DCC (OR
0.97, p = 2.4×10−10) exceeded genome-wide significance in the joint meta-analysis, but
rs1453867 in DISL32 (OR 0.98, p = 3.9×10−7) did not (Table 2). Thus, we demonstrate
genome-wide significant associations of CBP with loci tagged by rs12310519 (SOX5),
rs7833174 (CCDC26/GSDMC), and rs4384683 (DCC), with replication for rs12310519 in
SOX5.
Genome-wide meta-analysis of chronic back pain
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Characterization of variants in SOX5, CCDC26/GSDMC, and DCC
Functional characterization followed the same steps for each of the 3 loci that achieved
genome-wide significance in the joint meta-analysis. First, we examined cross-phenotype
genetic associations between each lead SNP and traits with possible conceptual links to CBP,
in look-ups of publicly and privately available GWAS datasets. Where the lead SNP was not
present in a dataset, we examined associations with the variant in highest LD with the lead
SNP. Second, we annotated lead variants and those in LD (r20.6) for consequences on gene
functions (using the combined annotation dependent depletion [CADD] score [21]), potential
regulatory functions (using RegulomeDB score[22]), and effects on gene expression (using
GTExv6 [23, 24]), and examined whether these variants resided in enhancer regions for
selected tissues with connections to the spine or pain processing (using data from the Road-
map Epigenomics Consortium [25, 26]) (Methods, S1 Text).
SOX5. Among CBP-related traits examined, the lead SNP in SOX5, rs12310519, was
most strongly associated with imaging-detected lumbar intervertebral disc degeneration
(p = 1.1×10−4; S5 Table)[27]. The highest CADD score among SOX5 variants was 10.52 for the
lead SNP in the region rs12310519, indicating it is predicted to be among the 10% most delete-
rious possible substitutions in the human genome (S1 Appendix). However, the overall regula-
tory potential of these variants was low according to RegulomeDB score (scores of 6 [‘minimal
binding evidence’]) (S1 Appendix). There were no meaningful associations with gene expres-
sion using GTExv6. The lead SNP rs12310519 and variants in LD (r2>0.6) contained active
enhancer marks in chondrogenic cells using Roadmap Epigenomics Consortium data (Fig 2,
S1 Appendix).
CCDC26/GSDMC. In look-ups of GWAS of selected traits with possible links to CBP
(S5 Table), the lead SNP rs7833174 was most strongly associated with height in UKB [28]
(p = 1.3×10−59) and hip circumference in UKB [28] (p = 1.8×10−5). The lead SNP rs7833174
was also associated with radiographic hip osteoarthritis[29] (p = 4.9×10−4) (S5 Table). All vari-
ants in CCDC26/GSDMC that were suggestively associated with CBP showed cross-phenotypic
associations with lumbar microdiscectomy for sciatica in a recent GWAS of Icelandic adults
[30] (S6 Table, lowest p = 5.6×10−12). The direction of effect on these other phenotypes was the
same as the direction of effect on CBP (i.e. the T allele associated with greater height, greater
risk of radiographic hip osteoarthritis, and greater risk of lumbar discectomy for sciatica was
also associated with greater CBP risk). The highest CADD score among CBP-associated vari-
ants at CCDC26/GSDMCwas 18.75 for rs6470778, indicating that this SNP is predicted to be
among the 5% most deleterious substitutions in the human genome, and the overall regulatory
potential of these variants was substantial according to Regulome DB score (highest Regulo-
meDB score of 2b [‘likely to affect binding’]) (S1 Appendix). In examination of effects on
gene expression using GTExv6, variants in LD with rs7833174 (r2>0.6) were also eQTLs
for GSDMC expression in esophageal mucosa, skin, and skeletal muscle (S1 Appendix,
p<5×10−8). The lead SNP rs7833174 and variants in LD (r2>0.6) contained active enhancer
marks located in regulatory regions for mesodermal cells, astrocytes, chondrogenic cells, and
osteoblasts in data from the Roadmap Epigenomics Consortium (Fig 2, S1 Appendix).
DCC. In look-ups of GWAS of selected traits with possible links to CBP (S5 Table), the
lead SNP rs4384683 was associated with depressive symptoms[31](p = 5.9×10−4), with the
same direction of effect (i.e the A allele was associated with less depressive symptoms and
lower CBP risk). The highest CADD score among variants at DCC that were suggestively asso-
ciated with CBP was 11.21 for rs2116378, indicating that rs2116378 is predicted to be among
the 10% most deleterious substitutions in the human genome, but the overall regulatory poten-
tial of these variants was low according to Regulome DB score (highest RegulomeDB score of
Genome-wide meta-analysis of chronic back pain
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Table 1. Cohorts in meta-analysis of genome-wide association studies of chronic back pain (European ancestry).
Cohort Study setting Country Sample
size
Chronic back pain
definition
Prevalence
(%)
Age (yr) BMI (kg/
m2)
Women
(%)
Cardiovascular Health
Study (CHS)
Community USA 2849 1 month of back
pain in consecutive
years
14.2% Cases (n = 404) 72.1 ± 5.1 27.3 ± 5.0 73.3%
Controls
(n = 2445)
72.1 ± 5.2 26.1 ± 4.3 59.6%
Framingham Heart
Study[19]
Community USA 2673 6 months of back
pain
21.0% Cases (n = 561) 67.7 ± 9.3 28.8 ± 5.8 62.2%
Controls
(n = 2112)
66.4 ± 9.1 28.0 ± 52 52.9%
Generation Scotland Population UK 5071 3 months of back
pain
26.0% Cases
(n = 1322)
54.9 ± 11.8 28.1 ± 5.7 66.7%
Controls
(n = 3749)
52.4 ± 12.7 26.4 ± 4.6 55.4%
Johnston County
Osteoarthritis Project
(JoCo)
Population USA 480 6 months of back
pain
38.8% Cases (n = 186) 72.0 ± 8.0 31.4 ± 6.3 65.0%
Controls
(n = 294)
73.0 ± 8.0 29.3 ± 5.2 58.4%
Mr. Os Sweden
Gothenburg Population Sweden 920 6 months of back
pain
14.2% Cases (n = 131) 75.3 ± 3.2 26.7 ± 3.9 0%
Controls
(n = 789)
75.3 ± 3.2 26.1 ± 3.4 0%
Malmo Population Sweden 948 6 months of back
pain
10.8% Cases (n = 102) 75.8 ± 3.1 27.2 ± 3.7 0%
Controls
(n = 846)
75.6 ± 3.2 26.4 ± 3.6 0%
Mr. Os US Community USA 4615 6 months of back
pain
14.1% Cases (n = 653) 74.6 ± 6.1 28.0 ± 4.1 0%
Controls
(n = 3962)
73.9 ± 5.9 27.3 ± 3.8 0%
Osteoarthritis Initiative
(OAI)
Community USA 2474 1 month of back
pain in consecutive
years
13.5% Cases (n = 335) 61.0 ± 9.1 28.9 ± 4.7 57.9%
Controls
(n = 2139)
61.7 ± 9.1 28.1 ± 4.5 53.2%
Rotterdam Study (RS)
RS-1 Community Netherlands 5965 6 months of back
pain
14.7% Cases (n = 877) 69.1 ± 9.2 26.7 ± 4.0 72.0%
Controls
(n = 5088)
70.0 ± 9.4 26.2 ± 3.7 58.3%
RS-2 Community Netherlands 1566 6 months of back
pain
36.7% Cases (n = 574) 65.3 ± 8.0 27.7 ± 4.2 66.7%
Controls
(n = 992)
64.6 ± 8.0 27.3 ± 4.1 55.4%
RS-3 Community Netherlands 3019 6 months of back
pain
38.2% Cases
(n = 1154)
57.4 ± 6.9 28.1 ± 4.8 59.5%
Controls
(n = 1865)
56.9 ± 6.7 27.4 ± 4.5 54.3%
Study of Osteoporotic
Fractures (SOF)
Community USA 3615 6 months of back
pain
16.3% Cases (n = 589) 72.1 ± 5.6 27.6 ± 5.3 100%
Controls
(n = 3026)
71.4 ± 5.2 26.6 ± 4.4 100%
10,001 Dalmatians
Vis Population Croatia 251 3 months of back
pain
22.3% Cases (n = 56) 67.3 ± 13.2 27.8 ± 4.4 69.6%
Controls
(n = 195)
63.7 ± 12.1 26.7 ± 4.0 52.8%
Korcula Population Croatia 773 3 months of back
pain
21.2% Cases (n = 164) 64.3 ± 12.9 28.0 ± 4.3 70.7%
Controls
(n = 609)
58.0 ± 14.9 27.0 ± 41 64.0%
UK Biobank Population United
Kingdom
120,024 3 months of back
pain
18.0% Cases
(n = 21,600)
57.3 ± 7.9 28.5 ± 5.4 54.0%
Controls
(n = 98,424)
57.0 ± 7.9 27.4 ± 4.8 52.4%
(Continued)
Genome-wide meta-analysis of chronic back pain
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007601 September 27, 2018 6 / 23
5) (S1 Appendix). There were no meaningful associations with gene expression using GTExv6.
In data from the Roadmap Epigenomics Consortium, the lead SNP rs4384683 and variants in
LD (r2>0.6) contained active enhancer marks in H9 human embryonic stem cell-derived neu-
ral cells (Fig 2, S1 Appendix).
Secondary analyses to examine interrelationships with height
Post hoc analyses among UKB1 participants from the discovery sample (n = 120,023) indicated
that associations with CBP for the lead variant in SOX5 were similar with and without adjust-
ment for height as a covariate, and in conditional analyses accounting for height (S1 Text,
S7 Table). Associations with CBP for the lead variant in CCDC26/GSDMCwere also similar
with and without adjustment for height as a covariate. However, associations with CBP were
markedly diminished when conditional on the lead height-associated variant in the region,
and associations with height were markedly diminished when conditioned on the lead CBP-
associated variant in the region (S7 Table). This suggests that the same functional variant is
responsible for association of CCDC26/GSDMC locus with height and CBP, although an alter-
native explanation is two functional variants in tight LD. Associations with CBP for the lead
variant in DCCwere similar with and without adjustment for height as a covariate, and in con-
ditional analyses accounting for height (S7 Table).
To examine possible causal effects of height on CBP, we conducted a two-sample Mende-
lian randomization (MR) analysis using genetic variants associated with standing height in the
GIANT consortium as the exposure, and the discovery phase GWAS meta-analysis of CBP as
the outcome. Results of the two-sample MR using 326 SNPs and the instruments involved are
available in the S2 Appendix. These instruments explained 10.1% of the variance in height,
with an average SNP-height F-statistic of 78.5, indicating substantial instrument strength. ORs
for CBP were 1.10 per standard deviation increase in height with inverse variance weighted
(IVW) regression (p<0.0001). However, there was significant heterogeneity among SNPs
(I2 = 0.35; p<0.0001), suggesting horizontal pleiotropy for at least some SNPs (S3 Appendix).
Estimates with other MR methods were directionally consistent, and all but MR-Egger regres-
sion were statistically significant: an OR for CBP of 1.09 per standard deviation increase in
height with MR-Egger regression (p = 0.19); 1.14 per standard deviation increase in height
with the weighted median method (p<0.0001), and 1.17 per standard deviation increase in
height with the weighted mode method (p = 0.02) (S3 Appendix). The magnitude of MR esti-
mates after excluding 14 outlier SNPs were very similar to the two-sample MR using 326
SNPs, but with substantially less heterogeneity amongst SNPs (I2 = 0.12; p = 0.04), just
exceeding nominal significance (S2 and S3 Appendices). MR-Egger intercepts were close to 0
with both the 326 SNP and 312 SNP instruments, and neither were statistically significant,
Table 1. (Continued)
Cohort Study setting Country Sample
size
Chronic back pain
definition
Prevalence
(%)
Age (yr) BMI (kg/
m2)
Women
(%)
TwinsUK Population-based
twin registry
United
Kingdom
2782 3 months of back
pain
29.6% Cases (n = 823) 56.7 ± 12.6 27.4 ± 5.3 90.3%
Controls
(n = 1959)
54.3 ± 13.9 26.0 ± 4.9 90.0%
Total of all cohorts - - 158,025 - - Cases
(n = 29,531)
- - -
Controls
(n = 128,494)
- - -
https://doi.org/10.1371/journal.pgen.1007601.t001
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suggesting no strong directional horizontal pleiotropy under the InSIDE (Instrument Strength
Independent on Direct Effect) assumption (S3 Appendix).
Secondary analyses to examine for influence of relatedness in UK Biobank. GWAS
analyses using linear mixed-effect models in UKB1 yielded associations between the 3 lead
SNPs and CBP that were very similar to the original analyses using logistic regression in terms
Fig 1. Manhattan plot for meta-analysis (discovery) of GWAS of chronic back pain (n = 158,025). GWAS = genome-wide association study. Results
use the linkage disequilibrium score regression (LDSR) intercept as a correction factor. Red line depicts genome-wide statistical significance (P
<5×10−8). Blue line depicts suggestive significance (P<5×10−7).
https://doi.org/10.1371/journal.pgen.1007601.g001
Table 2. Association results for chronic back pain: Meta-analysis (discovery), replication, and joint meta-analysis.
Discovery (Meta-analysis of CHARGE and
PainOmics cohorts + UKB1)a
(n = 158,025)
Replication (UKB2)b
(n = 283,752)
Joint Meta-Analysis
(Discovery-
Replication)c
(n = 441,777)
SNP rsID Chr:Posd Nearest Gene Location Alleles EAF OR SE p-value I2 Het. p-
value
OR SE p-valueb OR SE p-value
rs12310519e 12:23975219 SOX5 intronic T/C 0.16 1.08 0.013 7.2 x
10−10
0 0.95 1.06 0.009 5.3 x
10−11
1.07 0.008 4.5 x
10−19
rs1453867 2:232917899 DIS3L2 intronic T/C 0.65 0.95 0.010 7.7 x 10−8 13 0.31 0.98 0.007 0.021 0.97 0.006 3.9 x 10−7
rs7833174 8:130718772 CCDC26/
GSDMC
intergenic T/C 0.77 1.06 0.011 1.0 x 10−7 0 0.71 1.04 0.008 3.7 x 10−7 1.05 0.007 4.4 x
10−13
rs4384683 18:50379032 DCC intronic A/G 0.54 0.95 0.009 3.2 x 10−7 0 0.86 0.97 0.007 4.2 x 10−5 0.97 0.006 2.4 x
10−10
CHARGE = Cohorts for Heart and Aging Research in Genomic Epidemiology, UKB1 = UK Biobank participants from the interim data release[20], UKB2 = UK
Biobank participants not included in the interim data release, chr:pos = chromosome:position, alleles = effect/other, EAF = effect allele frequency OR = odds ratio, het. =
heterogeneity
Top variant at each locus meeting suggestive or genome-wide significance level in discovery stage (p<5.0x10-7).
aAfter genomic control using the LD score regression intercept
bReplication for rs12310519. The threshold for significance in replication of rs12310519 was p<0.05 (0.05/1)
cThe threshold for genome-wide significance in joint analysis was p<5×10−8
dBuild GRCh37/hg19
ers115392701 has merged into rs12310519
https://doi.org/10.1371/journal.pgen.1007601.t002
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of statistical significance, indicating no meaningful influence on the study results due to relat-
edness (S8 Table).
Heritability of CBP and genetic correlations
SNP heritability of CBP on the liability scale was 7.6%. Partitioned heritability by functional
category using stratified LD score regression showed significant enrichment (p = 0.0004) for
regions conserved in mammals, with 2.6% of SNPs explaining 40% of the SNP heritability of
CBP, without significant enrichment for other functional categories, including coding regions
(S4 Appendix). This pattern of partitioned heritability was broadly similar across cell type
groups, including central nervous system (CNS), connective tissue and bone, and skeletal mus-
cle, among others (S4 Appendix). Genetic correlations of nominal significance (range of rg
0.17–0.31, p<0.05) were found with anthropometric traits involving obesity or body fat distri-
bution (waist circumference, hip circumference, waist-hip ratios, overweight/obesity classes,
and BMI), but not with height (S9 Table). Larger magnitude nominally significant (p<0.05)
genetic correlations were also found with depression-related phenotypes (range of rg 0.46–
0.52), self-reported osteoarthritis (rg = 0.63), and ICD-10-defined osteoarthritis (rg = 0.49)
phenotypes.
Discussion
This study is the first meta-GWAS of CBP. This collaboration between two international con-
sortia for genomic studies of complex traits in the USA and Europe incorporated data from
16 cohorts and more than 441,000 participants of European ancestry across discovery and
replication samples. Our study identifies three novel associations with CBP for loci at SOX5,
CCDC26/GSDMC, and DCC.
CBP was most strongly associated with rs12310519 in an intronic region of the SOX5 gene.
The SOX genes are a family of transcription factors involved in virtually all phases of embry-
onic development, and are thought to determine the fate of many cell types. The SOX genes
are defined by containing the HMG (‘high mobility group’) box of a gene involved in sex
determination called SRY (‘sex determining region’) [32]. SOX5 and SOX6 have overlapping
Fig 2. Significant variants are co-localized with potential gene regulatory markers. The heatmap depicts the
percentage of variants in gene regulatory regions (associated with enhancers/promotors) in LD (r2>0.6) with
rs7833174 (CCDC26/GSDMC), rs12310519 (SOX5), and rs4384683 (DCC). We examined epigenetic histone marks in
selected cell types/tissues including chondrogenic, bone-related, neuronal and brain cells/tissues; mesodermal cells
(related to notochord); and psoas muscle (located proximal to the lumbar spine).
https://doi.org/10.1371/journal.pgen.1007601.g002
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functions and work together in close coordination that is necessary for efficient chondrogen-
esis [33]. Inactivation of SOX5 leads to minor defects in cartilage and skeletogenesis in mice,
whereas SOX5/SOX6 double knockouts have severe chondrodysplasia [34]. Together with
SOX9, SOX5 and SOX6 are sometimes referred to as the ‘master chondrogenic SOX trio’ [33,
35]. Prior work indicates an important role for SOX5 in articular cartilage and osteoarthritis
[36, 37], and such a role was also supported by our functional annotation showing that
rs12310519 (and SNPs in high LD) overlapped with potential regulatory regions for chondro-
genic cells. SOX5/6 are also essential for notochord development, and through this role they
are critical in the formation of the vertebral column, including the intervertebral discs [33, 35,
38]. Inactivation of SOX5 and/or SOX6 in mice leads to a range of abnormalities in the devel-
opment of spinal structures [38]. Although variants in SOX5 have not been reported in prior
GWAS of limb osteoarthritis (knee, hip, or hand) [39–46], the association of SOX5 with CBP
may involve the spinal structures specifically. Consistent with this, we found a cross-pheno-
typic association for the lead CBP-associated variant in SOX5 with imaging-detected lumbar
intervertebral disc degeneration in a prior GWAS meta-analysis [27]. Future GWAS may also
be useful to characterize other spine-related phenotypes besides disc degeneration, such as
osteoarthritis of the zygapophyseal (‘facet’) joint, the only true synovial joint in the spine [47].
The intergenic variants at CCDC26/GSDMC associated with CBP in the current study were
also previously found associated with lumbar microdiscectomy for sciatica due to interverte-
bral disc herniation.[30] These findings are intriguing, given that lumbar disc herniations (an
aspect of lumbar disc degeneration) have long been implicated as a cause of some forms of
back pain.[48] Recent studies have concluded that associations between imaging-detected
lumbar disc herniation and CBP are of modest magnitude.[10, 11] This might explain the
small magnitude association of the top variant at CCDC26/GSDMCwith CBP in the current
study (OR 1.08 in discovery), in contrast to the larger magnitude association seen with micro-
discectomy for sciatica (OR 1.23). Functional characterization of these intergenic variants sug-
gest the likely involvement of the gene GSDMC. GSDMC encodes the protein Gasdermin C,
part of the GSDM family of genes that is expressed in epithelial tissues. Although the specific
role of GSDMC in lumbar disc herniation and/or sciatica is unclear, GSDMC is associated with
differential methylation patterns in osteoarthritis-related cartilage and subchondral bone carti-
lage, [49, 50] consistent with our findings that variants in LD with rs4384683 were located in
potential regulatory regions in chondrocytes and osteoblasts. Our examination of univariate
cross-phenotypic genetic associations for CBP-associated variants at CCDC26/GSDMC also
suggest pleiotropy with radiographic hip OA for rs6470763.[29] Taken together, these data
suggest interconnections between variants at CCDC26/GSDMC and CBP involving cartilage,
osteoarthritis, and/or lumbar disc degeneration.
The third significant CBP-associated variant in our study was rs4384683, an intronic vari-
ant in the gene DCC (Deleted in Colorectal Carcinoma), which co-localized with regulatory
regions in neural embryonic stem cells. DCC encodes a transmembrane protein that is a recep-
tor for netrin-1, an axonal guidance molecule involved in the development of spinal and corti-
cal commissural neurons.[51] Interactions between DCC and netrin-1 are among the best-
studied axonal guidance processes, with key roles during development and in adulthood, and
they also affect angiogenesis.[52, 53] Increased expression of netrin-1 and DCC occurs in
degenerate human intervertebral discs compared to healthy control discs, and in nucleus
pulposus compared to annulus fibrosis.[54] Netrin-1/DCC might therefore mediate neurovas-
cular ingrowth into the intervertebral disc, which has long been implicated as a possible mech-
anism of chronic discogenic back pain.[54, 55] Given the well-known phenotypic correlation
between depression and CBP[56], however, another possible explanation for the link between
CBP and DCC (suggested by the cross-phenotype association of rs4384683 with depressive
Genome-wide meta-analysis of chronic back pain
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symptoms) is pleiotropy. Netrin-1/DCC interactions are also known to play a role in pain pro-
cessing in the spinal cord in animal models of mechanical allodynia.[52] Taken together, this
information suggests various potential mechanisms underlying the association between DCC
and CBP, including nociceptive pathways and/or the involvement of mood.
Some epidemiological studies report that greater height confers increased risk of back pain
[57–59], although a systematic review found no association.[60] Variants in CCDC26/GSDMC
associated with CBP in our meta-analysis were also reported to be associated with height in
prior GWAS; hence, post hoc analyses devoted special attention to the role of height in CBP.
These region-specific analyses showed that the association of SOX5 and DCC variants with
CBP was independent of height; however, CBP- and height-associated variants at CCDC26/
GSDMC were tightly linked and could not be disentangled in conditional analyses (S7 Table),
indicating that the association of variants in CCDC26/GSDMCwith both CBP and height
might be explained by biological pleiotropy or mediated pleiotropy (i.e. pleiotropy due to
causal effects)[61]. Mendelian randomization analysis, drawing on information from hun-
dreds of genetic markers distributed across the genome, suggested that height may have causal
effects on CBP, although with a degree of heterogeneity suggesting horizontal pleiotropy for
some SNPs. Such evidence of horizontal pleiotropy is common in MR studies of complex
traits,[62] and can be seen even in MR studies of exposure-outcome relationships where causal
effects are known.[63] Taken together, our findings suggest a causal component to the rela-
tionship between height and CBP, but do not exclude that height and CBP are also linked by
biological pleiotropy. Further more advanced studies should be conducted to corroborate our
findings. Prior studies demonstrating the vital role of SOX5 in normal vertebrate development
[33, 35, 38] are a reminder that measurements of human height used for GWAS may also
reflect vertebral column development; if associations with CBP and height are connected via
development of the vertebral column, it will be difficult to distinguish pleiotropy and causality
using genetic studies alone.
SNP-based heritability in the current study (8%) was considerably lower than estimates
from twin studies (~40%). This is a common situation with modern methods of estimating
heritability using genotype data, since such estimates reflect only one aspect of narrow-sense
heritability captured by the additive genetic components of common variants, excluding the
contributions of rare variants, non-additive effects, epistasis, or gene-environment interac-
tions.[64] Similar to what is seen with many other human traits,[65] there was significant
enrichment of SNP-based heritability of CBP for genetic regions that are conserved in mam-
mals. Despite the modest heritability of CBP (and other self-reported traits), we found signifi-
cant and large magnitude genetic correlations between CBP and other phenotypes that may be
risk factors for CBP or consequences of CBP, such as depression-, osteoarthritis- and obesity-
related traits (but not height). Future GWAS of CBP may benefit from taking these relation-
ships into account, either as covariates, or in multivariate GWAS designs.
A distinguishing feature of the current study as compared to many other GWAS is that
the CBP phenotype examined represents a symptom, rather than a disease or a biomarker.
Although successful GWAS of self-reported symptoms have been conducted which replicate
associations seen with more specific disease phenotypes,[66] our findings highlight potential
challenges of GWAS of CBP: despite being one of the largest international studies of CBP ever
conducted, our study detected only 3 significant associations with CBP. Still larger sample
sizes will be needed in future discovery efforts using this phenotype, or different genetic
approaches will be needed. A consequence of the nonspecific nature of the CBP phenotype is
that, unlike other musculoskeletal phenotypes such as osteoarthritis, the tissue correlates opti-
mal for conducting functional follow-up studies of findings from CBP GWAS are very unclear.
Most animal models for back pain rely on specific mechanisms of inducing pain, such as
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injuries to the intervertebral disc, zygapophyseal (‘facet’) joint, dorsal root ganglion, or muscle.
[67] However, each of these mechanisms likely explain only a certain portion of back pain
cases, and do not encompass the important psychosocial aspects of pain and pain reporting
that are highly relevant in humans. Despite the importance of psychosocial factors, our meta-
GWAS findings are a reminder that structural/anatomic factors involving spinal degeneration,
such as disc herniation or osteoarthritis of spinal structures (e.g. facet joints), remain poten-
tially important contributors to the CBP. While our study accounted for age by statistical
adjustment, the meta-analysis design including multiple cohorts of older adults may have led
to an overrepresentation of genetic variants associated with age-related conditions, such as
osteoarthritis. Future GWAS of CBP may benefit from a broader age range of participants,
stratification by back pain subtypes, simultaneously studying CBP and spinal degeneration/
fracture phenotypes, and examination of interactions between genetic markers for spinal
degeneration and markers for pain processing or axonal signaling (including DCC and
netrin-1).
Strengths of our study include its multicohort design and large sample size. A potential lim-
itation of our study was heterogeneity of the CBP phenotype used, a consequence of pooling
data from numerous cohorts using different definitions. Although this approach helped iden-
tify genetic associations shared across CBP subtypes, it might obscure associations pertinent
to specific subtypes of back pain. As an example, we examined chronic back pain rather than
chronic low back pain, since few of the included cohorts had available question items that iso-
lated the low back region specifically. Given the high agreement between general back pain
questions and low back-specific questions,[68] and since mid/upper back pain without con-
current low back pain is uncommon,[69] we expect that our results largely reflect genetic asso-
ciations with low back pain.[70] Despite phenotype heterogeneity, which would be expected to
bias the study towards the null, we successfully identified several associations of statistical sig-
nificance. Recent efforts to standardize CBP definitions may help to limit phenotype heteroge-
neity in future meta-GWAS of CBP.[3] Another aspect of the phenotype used in our meta-
analysis was that individuals with back pain of less than 3–6 months duration were included
as controls. This was done deliberately so as to focus on back pain of chronic duration as the
phenotype of interest. That said, GWAS examining back pain of any duration, or analyses
excluding those with non-chronic back pain, may find different results. Another possible
study limitation was lack of independence in the replication sample of UK Biobank partici-
pants from UKB2, given the same study base and methods between the UKB1 and UKB2
subcohorts. Our secondary analyses using linear mixed-effect models demonstrated similar
SNP-CBP associations for our top hits when accounting for relatedness within UKB1, but the
problem of relatedness across the two subcohorts (UKB1 vs. UKB2) remains. Finally, a limita-
tion of this meta-analysis was that only autosomal variants were analysed, since some included
cohorts did not analyze the X chromosome.
In summary, this meta-analysis of GWAS of CBP identified novel genetic associations with
CBP at SOX5, CCDC26/GSDMC, and DCC. Analysis of data from other GWAS and functional
genomics experiments suggest possible pleiotropic effects of these loci on other traits including
cartilage, osteoarthritis, lumbar disc degeneration, depression, and height/vertebral develop-
ment, and possible causal effects on CBP mediated through height.
Methods
Study design and populations
Discovery meta-analysis included adults of European ancestry from 16 population- and com-
munity-based cohorts: Cardiovascular Health Study (CHS), Framingham Heart Study (FHS),
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Generation Scotland (GS), Johnston County Osteoarthritis Project (JoCo), Osteoporotic Frac-
tures in Men (MrOS) Sweden (MrOS-Gothenburg and MrOS-Malmo), MrOS US, Osteoar-
thritis Initiative (OAI), Rotterdam Study (RS1, RS2, and RS3), Study of Osteoporotic Fractures
(SOF), 10,001 Dalmatians (Vis and Korcula), TwinsUK, and UKB participants from the
interim data release[20]. Replication was conducted among UKB European ancestry partici-
pants not included in the discovery stage (UKB2), and a joint (discovery-replication) meta-
analysis was performed. The separation of analyzed data from UKB into discovery (UKB1)
and replication phases (UKB2) reflects the history of this scientific collaboration, in that our
initial meta-analysis plan included only the UKB data then available to us and for which we
had obtained approval to use (UKB1 [the interim data release]). By the time our meta-analysis
was completed, all UKB data had become available; the remainder of UKB data was therefore
used for replication. Detailed descriptions of the study cohorts are provided in Table 1 and the
Supplemental Methods. This meta-analysis was approved by the Research and Development
Committee of VA Puget Sound Health Care System (RDIS 0010, MIRB 00903). Institutional
Review Board/Ethics Committee approvals at the individual study sites include those listed in
the S2 Text. Written or electronic consent was provided for all studies.
Chronic back pain (CBP) phenotype
There is no “gold-standard” definition for CBP. Consistent with the most commonly accepted
clinical and research definitions for CBP [3, 4], CBP cases were defined in this study using one
of 3 definitions depending on the cohort (Table 1, S10 Table): 1)3 months of back pain, 2)
6 months of back pain, and 3)1 month of back pain in consecutive years (reflecting12
months of back pain). For each cohort, the comparison group (“controls”) was comprised
of those who reported not having back pain or reported back pain of insufficient duration to
be included as a case. This study used a general definition examining chronic ‘back pain’, as
opposed to a more specific chronic ‘low back pain’ definition, due to the fact that most of the
included cohorts did not include question items permitting localization of pain to the low
back or lumbar region specifically.
Genotyping
Details of genotyping, quality control, imputation methods, and genome-wide analysis for
each cohort were study-specific (S1 and S2 Tables). In brief, genotyping was performed using
commercially available genome-wide arrays. Imputation of single nucleotide polymorphisms
(SNPs) and insertions/deletions (indels) was performed using reference panels from 1000
Genomes phase 1 version 3 or phase 3,[71] or the Haplotype Reference Consortium.[72] Anal-
yses of UKB participants was restricted to the White British ancestry subset who self-report as
White, British, and have very similar genetic ancestry backgrounds based on the results of
principal components analysis (PCA); further quality control followed recommended practices
for UKB[73] (S1 Table).
Statistical analysis
We conducted genome-wide association analyses in each of the 16 cohorts, and subsequent
meta-analysis of autosomal SNPs to combine results from all cohorts. Each site conducted
GWAS using logistic regression models with additive genetic effects to test for associations
between each variant and CBP as a binary trait. These models adjusted for age, sex, study-spe-
cific covariates, and population substructure using principal components (S2 Table). Height
and body mass index (BMI), calculated as weight in kilograms divided by height in meters
squared, were not included as covariates in site-specific GWAS, since these traits might lie
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along the causal pathway or (in the case of BMI) reflect a consequence of CBP. Harmonization
and quality control of GWAS results from each cohort were conducted using the EasyQC soft-
ware package in the R statistical environment (v3.2.2), using methods described previously.
[74] After removal of SNPs with low minor allele frequencies (<0.005 for UKB, <0.03 for Vis,
<0.01 for other cohorts) or imputation quality (<0.7 for UKB,<0.6 for other cohorts), devia-
tion from Hardy-Weinberg equilibrium (p< 1 x 10–6), low number of cases (<15) or controls
(<15), large absolute values of beta coefficient (10), and low minor allele count (10), call
rate<0.95, the range of SNPs included in the meta-analysis was between 6,205,227 (Croatia-
Vis) and 9,775,703 (MrOs-Gothenburg) (S2 Table). Fixed-effect inverse-variance weighted
meta-analysis was performed with METAL version 2011-03-25 (http://csg.sph.umich.edu/
abecasis/metal/), using the LDsr intercept as a correction factor. The meta-analysis was filtered
for variants with fewer than 125,000 informative participants, to ensure that SNP-CBP associa-
tions were informed by a plurality of cohorts, and not only the UKB interim data release. For
this reason, only variants with MAF<0.01 (SNPs) were included in the meta-analysis. Quality
control and meta-analysis were conducted twice, independently of each other, by researchers
at the University of Washington (MP and PS) and at PolyOmica (YT, YA, and LCK). The
results from the two centers were compared to ensure accuracy. Q-Q and Manhattan plots
were generated in R. We conducted conditional and joint (COJO) analysis using summary
data (http://cnsgenomics.com/software/gcta/#About) to examine associations conditional on
the most significant variant at each locus (S1 Text).
The most highly-associated variants at genome-wide significant loci were subjected to repli-
cation among UKB participants not included in the discovery sample (UKB2). Analysis in
UKB2 used logistic regression with additive genetic effects, adjusting for age, sex, array, and
principal components (S2 Table); significant replication was defined using a Bonferroni-cor-
rected threshold of p<0.05 divided by the number of genome-wide significant loci. The most
highly-associated variants at loci with suggestive significance were selected for a joint (discov-
ery-replication) meta-analysis using p<5×10−8 to define genome-wide significance. Further
details regarding analysis are provided in S1 Text. A post hoc analysis was conducted to stratify
the discovery phase meta-analysis by the CHARGE cohorts (meta-analysis of 15 GWAS) vs.
the UKB interim data release cohort (S4 Table).
For genome-wide significant variants, we examined GWAS associations with selected traits
with possible links to CBP (anthropometrics, arthritis, depression and depressive symptoms,
and imaging-based spinal degeneration) in publicly and privately available GWAS datasets.
We conducted functional annotation using FUMA (http://fuma.ctglab.nl). FUMA draws upon
multiple publicly available databases, annotating variants for consequences on gene functions
using the combined annotation dependent depletion (CADD) score,[21] potential regulatory
functions (RegulomeDB score),[22] and effects on gene expression using expression quantita-
tive trait loci (eQTLs) of different tissue types (GTExv6) [23, 24] (S1 Text). The higher the
CADD score, the more potentially deleterious is the variant. A CADD score of10 indicates a
variant predicted to be among the 10% most deleterious substitutions involving the human
genome, a score of20 indicates a variant among the 1% most deleterious, and so forth.[21]
We used data from the Roadmap Epigenomics Project to evaluate whether the lead variants at
each locus and those in LD (r2>0.6) reside in enhancer regions for selected tissues with possi-
ble conceptual connections to the spine via roles in chondrogenesis, vertebral development,
muscle, and pain processing in the CNS.[25, 26].
Because two CBP-associated variants were found to be associated with height in prior pub-
lished GWAS, we conducted post hoc region-specific secondary GWAS analyses accounting
for height, among UKB participants from the discovery stage. Further details of functional
annotation and secondary analyses are provided in S1 Text. We also conducted a two-sample
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Mendelian randomization to examine potential causal effects of height on CBP using signifi-
cant variants associated with standing height from the GIANT consortium as the exposure,
and the discovery phase meta-analysis of CBP, using the R package MRbase. We used the
inverse-variance weighted regression (IVW) approach as our primary analysis method,[75]
and additional analyses with other MR methods (MR-Egger regression, weighted median
function, and weighted mode); presenting the results yielded from different MR methods is
recommended to demonstrate sensitivity to different patterns of assumption violations.[63,
76] We examined heterogeneity among SNPs using forest plots, funnel plots, heterogeneity
statistics, and the MR-Egger intercept test for directional horizontal pleiotropy. Further details
of MR methods are provided in the S1 Text.
Given that 30% of UKB participants are related to at least one other person in the cohort,
we also conducted post hoc secondary GWAS in UKB1 to examine whether relatedness might
have influenced our results. These analyses used linear mixed-effect models (BOLT-LMM),
adjusting for age, sex, study-specific covariates, and principal components. The statistical sig-
nificance of GWAS results for UKB1 using BOLT-LMM were descriptively compared with the
original results using logistic regression, for the lead variants achieving suggestive significance
in the GWAS meta-analysis.
Finally, we used LDsr of summary-level GWAS results from the discovery stage to estimate
heritability due to common autosomal SNPs and genetic correlations.[18] We transformed the
observed SNP heritability to the liability scale, in order to make heritability estimates for CBP
comparable with traditional heritability estimates from twin studies.[64] We used stratified
LDsr to partition heritability across functional categories of the genome, using methods
described previously.[65] The threshold for determining the statistical significance of 53 func-
tional categories in partitioning heritability was set at p<9.4 x 10–4 (0.05/53). Further details
of methods for partitioning heritability are provided in the S4 Appendix. We used cross-trait
LDsr and publicly available meta-GWAS results from LDhub to examine genetic correlations
with selected traits with possible links to CBP: anthropometrics (height, waist/hip circumfer-
ence, BMI, and overweight/obesity), depression and depressive symptoms, osteoarthritis, and
rheumatoid arthritis.[77, 78]
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